NEW YORK — Avalon GloboCare and Qi Diagnostics on Tuesday announced their intention to codevelop a breathalyzer device for screening and the early detection of lung cancer.
The firms will have joint ownership of any intellectual property generated in the codevelopment of a lung cancer breathalyzer product, Avalon said in a statement. The Freehold, New Jersey-based company develops cellular therapeutics and precision diagnostics and provides clinical laboratory services. Meanwhile, Qi Diagnostics develops a breath-based test called KetoAir, which leverages nanosensors and AI to detect volatile organic compounds. The device is a companion diagnostic and monitoring tool for ketogenic dietary management.
The companies revealed their intention to develop their lung cancer screening and detection test as part of a larger announcement of a deal under which Avalon will exclusively distribute the KetoAir breathalyzer and related accessories in North America, South America, the UK, and the EU. KetoAir will initially be targeted to the diabetes reversal and weight management markets, Avalon said.
Financial and other terms of the deal were not disclosed, although Avalon noted that the companies plan to enter a definitive agreement with the final terms and pricing but that there is no assurance the agreement will be entered into on terms acceptable to Avalon.